Date: 2013-06-20
Type of information: Initiation of preclinical development
phase:
Announcement:
Company: Protalix BioTherapeutics (Israel)
Product: PRX-107
Action
mechanism: PRX-107 is a plant cell recombinant human Alpha1-antitrypsin (AAT) under development for the treatment of emphysema due to hereditary AAT deficiency, to be administered by inhalation.
Disease: emphysema from heredity alpha-1 antitrypsin deficiency (AATD)
Therapeutic area: Respiratory diseases - Genetic diseases - Rare diseases
Country:
Trial details:
Latest
news: * On June 20, 2013, Protalix BioTherapeutics has held an Analyst Event in which included the disclosure of new data regarding new compounds in development. One of this compound, PRX-107, is the Company\'s proprietary plant cell recombinant human Alpha1-antitrypsin (AAT) under development for the treatment of emphysema due to hereditary AAT deficiency, to be administered by inhalation. In preclinical studies, PRX-107 demonstrated the ability to rescue elastase induced lung damage in rats and as effective as a plasma-derived reagent. The Company plans to hold a pre-IND meeting with the FDA in the second half of 2013 to discuss next steps for this compound.
